Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years
Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years
Autologous stem cell transplantation remains the gold standard of treatment for newly
 diagnosed patients under the age of 65. Even though it is also regularly performed above the
 age of 65, there are very few data in this patient population. The investigators will capture
 safety and efficacy data in that setting.
Newly diagnosed myeloma patients above the age of 65 years will be treated the following way:
 Bortezomib (Velcade®) based induction treatment (either Velcade Dexamethasone, Velcade
 Thalidomide Dexamethasone (VTD) or Velcade Cyclophosphamide Dexamethasone (VCD)). After the
 induction phase, for patients at least in partial remission, a collection of peripheral blood
 stem cells (PBSC) is done according to each center practice. High dose melphalan (140 mg/m2)
 followed by PBSC autologous transplantation is then performed. Three months post transplant,
 2-3 cycles (similar to the initial induction phase) of consolidation are allowed.
Inclusion Criteria:

 -  newly diagnosed MM,

 -  age over 65,

 -  measurable disease

 Exclusion Criteria:

 -  Patients less than 65 and/or not proceeding to autologous PBSC transplantation